Alex Matter

3.2k total citations · 1 hit paper
36 papers, 2.1k citations indexed

About

Alex Matter is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Alex Matter has authored 36 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Oncology and 8 papers in Immunology. Recurrent topics in Alex Matter's work include Immunotherapy and Immune Responses (4 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer Genomics and Diagnostics (3 papers). Alex Matter is often cited by papers focused on Immunotherapy and Immune Responses (4 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer Genomics and Diagnostics (3 papers). Alex Matter collaborates with scholars based in Switzerland, Singapore and United States. Alex Matter's co-authors include Elisabeth Buchdunger, Juerg Zimmermann, Renaud Capdeville, Urs Regenass, Klaus Schieweck, A.S. Bhatnagar, Brian Druker, Enrico Curschellas, Max M. Burger and T. Tao and has published in prestigious journals such as Nature, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Alex Matter

36 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

2002 1.1k citations Renaud Capdeville, Elisabeth Buchdunger et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alex Matter Switzerland	17	941	410	394	338	204	36	2.1k
Daikichi Fukushima Japan	19	793 0.8×	232 0.6×	313 0.8×	139 0.4×	86 0.4×	31	1.9k
Kenji Sugita Japan	23	1.4k 1.5×	538 1.3×	360 0.9×	104 0.3×	206 1.0×	83	2.9k
Terutoshi Kimura Japan	29	2.3k 2.4×	376 0.9×	352 0.9×	113 0.3×	241 1.2×	119	3.4k
Carol S. Lim United States	21	1.3k 1.4×	319 0.8×	141 0.4×	184 0.5×	372 1.8×	72	2.1k
Gerard M. McGeehan United States	22	1.1k 1.1×	560 1.4×	194 0.5×	593 1.8×	109 0.5×	60	2.1k
Masato Maruyama Japan	18	808 0.9×	303 0.7×	128 0.3×	197 0.6×	125 0.6×	74	1.5k
Raymond E. Jones United States	25	1.7k 1.8×	628 1.5×	584 1.5×	106 0.3×	311 1.5×	40	2.6k
Lajos Gera United States	29	1.3k 1.4×	528 1.3×	347 0.9×	258 0.8×	86 0.4×	106	2.8k
Jean‐Baptiste Telliez United States	28	1.2k 1.3×	807 2.0×	293 0.7×	274 0.8×	285 1.4×	36	2.9k
C. Chandra Kumar United States	24	1.8k 1.9×	449 1.1×	153 0.4×	104 0.3×	214 1.0×	43	2.5k

Countries citing papers authored by Alex Matter

Since Specialization

Citations

This map shows the geographic impact of Alex Matter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Matter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Matter more than expected).

Fields of papers citing papers by Alex Matter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Matter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Matter. The network helps show where Alex Matter may publish in the future.

Co-authorship network of co-authors of Alex Matter

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Matter. A scholar is included among the top collaborators of Alex Matter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Matter. Alex Matter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hörnberg, Hanna, Enrique Pérez‐Garci, Dietmar Schreiner, et al.. (2020). Rescue of oxytocin response and social behaviour in a mouse model of autism. Nature. 584(7820). 252–256. 103 indexed citations

Teneggi, Vincenzo, et al.. (2018). Drugs’ development in acute heart failure: what went wrong?. Heart Failure Reviews. 23(5). 667–691. 8 indexed citations

Low, Jenny G., Lawrence Lee, Eng Eong Ooi, et al.. (2014). Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine. 32(39). 5041–5048. 60 indexed citations

Skibinski, David, Brendon J. Hanson, Veronika von Messling, et al.. (2013). Enhanced Neutralizing Antibody Titers and Th1 Polarization from a Novel Escherichia coli Derived Pandemic Influenza Vaccine. PLoS ONE. 8(10). e76571–e76571. 22 indexed citations

Schreiber, Mark, et al.. (2009). Protein kinases as antibacterial targets. Current Opinion in Cell Biology. 21(2). 325–330. 47 indexed citations

Matter, Alex & Thomas H. Keller. (2008). Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions. Drug Discovery Today. 13(7-8). 347–352. 11 indexed citations

Herrling, Paul L., Markus Rudin, & Alex Matter. (2005). Imaging in Drug Discovery and Early Clinical Trials. Birkhäuser Basel eBooks. 7 indexed citations

Capdeville, Renaud, Elisabeth Buchdunger, Juerg Zimmermann, & Alex Matter. (2002). Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews Drug Discovery. 1(7). 493–502. 1067 indexed citations breakdown →

Buchdunger, Elisabeth, Alex Matter, & Brian Druker. (2001). Bcr-Abl inhibition as a modality of CML therapeutics. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1551(1). M11–M18. 72 indexed citations

10.

Matter, Alex. (2001). Tumor angiogenesis as a therapeutic target. Drug Discovery Today. 6(19). 1005–1024. 95 indexed citations

11.

Regenass, Urs, Giorgio Caravatti, Helmut Mett, et al.. (1992). New S-adenosylmethionine decarboxylase inhibitors with potent antitumor activity.. PubMed. 52(17). 4712–8. 49 indexed citations

12.

Geleick, Detlef, Hansjakob Müller, Alex Matter, J. Torhorst, & Urs Regenass. (1990). Cytogenetics of breast cancer. Cancer Genetics and Cytogenetics. 46(2). 217–229. 53 indexed citations

13.

Schieweck, Klaus, et al.. (1989). CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties. Cancer Chemotherapy and Pharmacology. 23(6). 341–347. 3 indexed citations

14.

Curschellas, Enrico, Alex Matter, & Urs Regenass. (1987). Immunolocalization of cytoskeletal elements in human mammary epithelial cells. European Journal of Cancer and Clinical Oncology. 23(10). 1517–1527. 12 indexed citations

15.

Regenass, Urs, Marcel A. Müller, Enrico Curschellas, & Alex Matter. (1987). Anti‐tumor effects of tumor necrosis factor in combination with chemotherapeutic agents. International Journal of Cancer. 39(2). 266–273. 63 indexed citations

16.

Meyer, Thomas, Doriano Fabbro, Urs Eppenberger, & Alex Matter. (1986). The lipophilic muramyltripeptide MTP-PE, a biological response modifier, is an activator of protein kinase C. Biochemical and Biophysical Research Communications. 140(3). 1043–1050. 4 indexed citations

17.

Matter, Alex, et al.. (1982). Antiproliferative action of a novel fluorinated uridine analog, 5'-deoxy-5-fluorouridine, measured in vitro and in vivo on four different murine tumor lines.. PubMed. 42(6). 2412–5. 15 indexed citations

18.

Matter, Alex, et al.. (1979). Interaction of Retinoic Acid and 3-Methylcholanthrene on the Fine Structure of Mouse Prostate Epithelium in Vitro. JNCI Journal of the National Cancer Institute. 11 indexed citations

19.

Matter, Alex. (1974). THE DIFFERENTIATION PATHWAY OF T LYMPHOCYTES. The Journal of Experimental Medicine. 140(2). 566–577. 16 indexed citations

20.

Matter, Alex, et al.. (1971). Autophagic vacuoles in experimental atrophy. Experimental and Molecular Pathology. 14(2). 158–175. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact